---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-012519"
form_type: "8-K"
ticker: "PAHC"
cik: "0001069899"
company_name: "PHIBRO ANIMAL HEALTH CORP"
filed_at: "2024-08-28T23:59:59+00:00"
generated_at: "2026-05-31T07:06:31.043747+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Phibro Q4 net sales up 7% to $273.2M; FY2025 guidance sees 10% adjusted EBITDA growth

## Summary
- Q4 GAAP net income of $0.8M ($0.02 EPS) vs $11.5M ($0.28 EPS) YoY; adjusted EPS $0.41 (+10%).
- Full-year net sales $1,017.7M (+4%); adjusted EBITDA $111.2M (-1%); adjusted EPS $1.19 (-1%).
- FY2025 guidance: net sales $1.04B-$1.09B, adjusted EBITDA $118M-$126M, adjusted EPS $1.22-$1.37.
- Free cash flow $46.4M; total debt $489.1M; cash & short-term investments $114.6M; gross leverage 4.4x.
- Guidance excludes proposed Zoetis MFA acquisition; company notes strength in Q4 Animal Health segment.

## SEC filing metadata
- accession: 0001558370-24-012519
- form_type: 8-K
- ticker: PAHC
- cik: 0001069899
- company_name: PHIBRO ANIMAL HEALTH CORP
- filed_at: 2024-08-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069899/000155837024012519/0001558370-24-012519-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069899/000155837024012519/pahc-20240828x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-012519
- JSON: https://secwatch.observer/filing/0001558370-24-012519.json
- Plain text: https://secwatch.observer/filing/0001558370-24-012519.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.